These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36207403)

  • 41. Screening and optimization of phage display cyclic peptides against the WDR5 WBM site.
    Song L; Cao J; Chen L; Du Z; Zhang N; Cao D; Xiong B
    RSC Med Chem; 2023 Oct; 14(10):2048-2057. PubMed ID: 37859722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
    Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
    Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
    Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
    Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Small molecule WDR5 inhibitors down-regulate lncRNA expression.
    Chang JY; Neugebauer C; Mues Genannt Koers A; 't Hart P
    RSC Med Chem; 2024 Feb; 15(2):636-640. PubMed ID: 38389889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity.
    Kaneda D; Iehara T; Kikuchi K; Sugimoto Y; Nakagawa N; Yagyu S; Miyachi M; Konishi E; Sakai T; Hosoi H
    Pediatr Int; 2022 Jan; 64(1):e15159. PubMed ID: 35727889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
    Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
    Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
    Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
    Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
    Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
    Poon E; Liang T; Jamin Y; Walz S; Kwok C; Hakkert A; Barker K; Urban Z; Thway K; Zeid R; Hallsworth A; Box G; Ebus ME; Licciardello MP; Sbirkov Y; Lazaro G; Calton E; Costa BM; Valenti M; De Haven Brandon A; Webber H; Tardif N; Almeida GS; Christova R; Boysen G; Richards MW; Barone G; Ford A; Bayliss R; Clarke PA; De Bono J; Gray NS; Blagg J; Robinson SP; Eccles SA; Zheleva D; Bradner JE; Molenaar J; Vivanco I; Eilers M; Workman P; Lin CY; Chesler L
    J Clin Invest; 2020 Nov; 130(11):5875-5892. PubMed ID: 33016930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.
    Gangoda L; Keerthikumar S; Fonseka P; Edgington LE; Ang CS; Ozcitti C; Bogyo M; Parker BS; Mathivanan S
    Oncotarget; 2015 May; 6(13):11175-90. PubMed ID: 25883214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overlapping characteristics of weak interactions of two transcriptional regulators with WDR5.
    Ahmad M; Imran A; Movileanu L
    Int J Biol Macromol; 2024 Feb; 258(Pt 2):128969. PubMed ID: 38158065
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
    Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines.
    Mercatelli D; Balboni N; Palma A; Aleo E; Sanna PP; Perini G; Giorgi FM
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33525507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.